Here's a piece of news for anyone following the pharmaceutical space: Teva Pharmaceutical Industries Ltd (TEVA) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for something called olanzapine extended-release injectable suspension. That's a mouthful, so let's just call it TEV-'749 for now.
This is a potential new treatment for schizophrenia, and it's a monthly injection. The idea is pretty straightforward—if you only have to get a shot once a month instead of taking pills every day, you're probably more likely to stick with the treatment. That's what Teva is aiming for here: improving what they call "treatment adherence" for people living with schizophrenia.
The application is based on results from a Phase 3 trial named SOLARIS. The trial showed that TEV-'749 has an efficacy and safety profile that's consistent with the olanzapine formulations that are already out there. But here's a potentially useful twist: when administered as a once-monthly subcutaneous injection, the trial showed no evidence that patients needed post-injection monitoring. That's typically required for other long-acting formulations, so not needing it could be a practical advantage.
Teva is using a proprietary technology called SteadyTeq from a company named Medincell for this drug. It's a copolymer tech designed to provide a controlled, steady, sustained release of the olanzapine. The acceptance of this NDA is a significant step for Teva as it looks to expand its offerings in the schizophrenia treatment market.
Speaking of that market, Teva already has another schizophrenia drug called Uzedy (risperidone). It brought in revenues of $191 million in fiscal 2025, which was up 63% and actually came in above management's expectation of $190 million to $200 million. So, the company has some existing momentum in this therapeutic area.
Now, let's talk about the stock. From a technical analysis perspective, things look a bit mixed. The stock is currently trading 10.5% below its 20-day simple moving average and 8.2% below its 100-day simple moving average. That suggests some short-term weakness. Over the past 12 months, though, shares are up 12.4%, and they're positioned closer to their 52-week highs than their lows.
The Relative Strength Index is sitting right at 50.00, which is neutral territory. The MACD, however, is at 0.10, which is below its signal line of 0.15, suggesting there's some bearish pressure on the stock. So you've got neutral RSI and a bearish MACD—mixed momentum, as they say. Key resistance is seen at $37.00, with key support at $32.00.
What do the analysts think? The consensus rating is a "Buy," with an average price target of $34.09. And recently, a few firms have been making moves:
- Truist Securities: Maintained a Buy rating and raised their target price to $42.00 on February 18.
- Goldman Sachs: Maintained a Buy rating and raised their target price to $45.00 on February 9.
- Barclays: Maintained an Overweight rating and raised their target price to $38.00 on January 30.
As for the price action, Teva Pharmaceutical shares were down 1.37% at $33.75 during premarket trading on Monday, according to market data.
